

Top 5 Combinations by Therapeutic Potential (Synergy – Resistance)

Cancer Type	Triple	Synergy	Resistance	Drugs
Non-Seminomatous Germ Cell T	FYN + SRC + STAT3	0.95	0.15	dasatinib+dasatinib+napabucasin
Squamous Cell Carcinoma of t	FYN + SRC + STAT3	0.95	0.15	dasatinib+dasatinib+napabucasin
Retinoblastoma	BCL2L1 + CDK6 + ERBB2	0.60	0.00	navitoclax+palbociclib+trastuzumab
Non-Cancerous	CDK6 + FYN + STAT3	0.94	0.35	palbociclib+dasatinib+napabucasin
Neuroblastoma	CDK6 + FYN + STAT3	0.94	0.35	palbociclib+dasatinib+napabucasin